Misplaced Pages

Revision as of 21:07, 1 September 2018

Gilbert's syndrome
Other names	Meulengracht syndrome, Gilbert-Lereboullet syndrome, hyperbilirubinemia Arias type, hyperbilirubinemia type 1, familial cholemia, familial nonhemolytic jaundice
Bilirubin
Pronunciation	/ʒiːlˈbɛərz/ zheel-BAIRZ
Specialty	Gastroenterology
Symptoms	None, slight jaundice
Complications	Usually none
Causes	Genetic
Differential diagnosis	Crigler-Najjar syndrome, Rotor syndrome, Dubin-Johnson syndrome
Treatment	None typically needed
Frequency	~5%

Gilbert's syndrome (GS) is a mild liver disorder in which the liver does not properly process bilirubin. Many people never have symptoms. Occasionally a slight yellowish color of the skin or whites of the eyes may occur. Other possible symptoms include feeling tired, weakness, and abdominal pain.

Gilbert's syndrome is due to a mutation in the UGT1A1 gene which results in decreased activity of the bilirubin uridine diphosphate glucuronosyltransferase enzyme. It is typically inherited in an autosomal recessive pattern and occasionally in an autosomal dominant pattern depending on the type of mutation. Episodes of jaundice may be triggered by stress such as exercise, menstruation, or not eating. Diagnosis is based on higher levels of unconjugated bilirubin in the blood without either signs of other liver problems or red blood cell breakdown.

Typically no treatment is needed. If jaundice is significant phenobarbital may be used. Gilbert's syndrome affects about 5% of people in the United States. Males are more often diagnosed than females. It is often not noticed until late childhood to early adulthood. The condition was first described in 1901 by Augustin Nicolas Gilbert.

Signs and symptoms

Jaundice

Gilbert's syndrome produces an elevated level of unconjugated bilirubin in the bloodstream, but normally has no serious consequences. Mild jaundice may appear under conditions of exertion, stress, fasting, and infections, but the condition is otherwise usually asymptomatic. Severe cases are seen by yellowing of the skin tone and yellowing of the sclera in the eye.

GS has been reported to possibly contribute to an accelerated onset of neonatal jaundice, especially in the presence of increased red blood cell destruction due to diseases such as G6PD deficiency. This situation can be especially dangerous if not quickly treated, as the high bilirubin causes irreversible neurological disability in the form of kernicterus.

Detoxification of certain drugs

The enzymes that are defective in GS - UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) - are also responsible for some of the liver's ability to detoxify certain drugs. For example, Gilbert's syndrome is associated with severe diarrhea and neutropenia in patients who are treated with irinotecan, which is metabolized by UGT1A1.

While paracetamol (acetaminophen) is not metabolized by UGT1A1, it is metabolized by one of the other enzymes also deficient in some people with GS. A subset of people with GS may have an increased risk of paracetamol toxicity.

Cardiovascular effects

Several analyses have found a significantly decreased risk of coronary artery disease (CAD) in individuals with GS.

Specifically, people with mildly elevated levels of bilirubin (1.1 mg/dl to 2.7 mg/dl) were at lower risk for CAD and at lower risk for future heart disease. These researchers went on to perform a meta-analysis of data available up to 2002, and confirmed the incidence of atherosclerotic disease (hardening of the arteries) in subjects with GS had a close and inverse relationship to the serum bilirubin. This beneficial effect was attributed to bilirubin IXα which is recognized as a potent antioxidant, rather than confounding factors such as high-density lipoprotein levels.

This association was also seen in long-term data from the Framingham Heart Study. Moderately elevated levels of bilirubin in people with GS and the (TA)₇/(TA)₇ genotype were associated with one-third the risk for both coronary heart disease and cardiovascular disease as compared to those with the (TA)₆/(TA)₆ genotype (i.e. a normal, nonmutated gene locus).

In a Korean population, serum levels of bilirubin (elevated in Gilbert Syndrome) were negatively associated with stroke risk in men, further supporting the protective role of bilirubin in cardiovascular disease-- however, this study excluded those with Gilbert Syndrome.

Platelet counts and MPV are decreased in patients with Gilbert's Syndrome. The elevated levels of bilirubin and decreasing levels of MPV and CRP in Gilbert's syndrome patients may have an effect on the slowing down of the atherosclerotic process.

Other

Symptoms, whether connected or not to GS, have been reported in a subset of those affected: feeling tired all the time (fatigue), difficulty maintaining concentration, unusual patterns of anxiety, loss of appetite, nausea, abdominal pain, loss of weight, itching (with no rash), and others, but scientific studies found no clear pattern of adverse symptoms related to the elevated levels of unconjugated bilirubin in adults. However, other substances glucuronidized by the affected enzymes in Gilbert's syndrome sufferers could theoretically, at their toxic levels, cause these symptoms. Consequently, debate exists about whether GS should be classified as a disease. However, Gilbert's syndrome has been linked to an increased risk of gallstones.

In agreement with the antioxidant effects of elevated levels of bilirubin, Type 1 Diabetics with Gilbert Syndrome had lower A1C (a marker of glycated hemoglobin that reflects a running 3 month average of blood glucose levels) scores than matched controls with Type 1 Diabetes, though there seemed to be no protective effect of bilirubin levels on rates of microalbuminuria, which is an early marker for renal damage in diabetics.

Non-Alcoholic Fatty Liver Disease (NAFLD) is linked to oxidative stress in addition to insulin resistance and obesity, and serum levels of bilirubin were inversely associated with rates of Non-Alcoholic Fatty Liver Disease in Korean population.

Genetics

Gilbert's syndrome is a phenotypic effect, characterized by mild jaundice due to increased unconjugated bilirubin, that arises from several different genotypic variants of the gene for the enzyme responsible for changing bilirubin to the conjugated form.

Gilbert's syndrome is characterized by a 70–80% reduction in the glucuronidation activity of the enzyme, (UGT1A1). The UGT1A1 gene is located on human chromosome 2.

More than 100 variants of the UGT1A1 gene are known, designated as UGT1A1*n (where n is the general chronological order of discovery), either of the gene itself or of its promoter region. UGT1A1 is associated with a TATA box promoter region; this region most commonly contains the genetic sequence A(TA)₆TAA; this variant accounts for about 50% of alleles in many populations. However, several allelic polymorphic variants of this region occur, the most common of which results from adding another dinucleotide repeat TA to the promoter region, resulting in A(TA)₇TAA, which is called UGT1A1*28; this common variant accounts for about 40% of alleles in some populations, but is seen less often, around 3% of alleles, in Southeast and East Asian people and Pacific Islanders.

In most populations, Gilbert's syndrome is most commonly associated with homozygous A(TA)₇TAA alleles. In 94% of GS cases, two other glucuronosyltransferase enzymes, UGT1A6 (rendered 50% inactive) and UGT1A7 (rendered 83% ineffective), are also affected.

However, Gilbert's syndrome can arise without TATA box promoter polymorphic mutations; in some populations, particularly healthy Southeast and East Asians, Gilbert's syndrome is more often a consequence of heterozygote missense mutations (such as Gly71Arg also known as UGT1A1*6, Tyr486Asp also known as UGT1A1*7, Pro364Leu also known as UGT1A1*73) in the actual gene coding region, which may be associated with significantly higher bilirubin levels.

Because of its effects on drug and bilirubin breakdown and because of its genetic inheritance, Gilbert's syndrome can be classed as a minor inborn error of metabolism.

Diagnosis

People with GS predominantly have elevated unconjugated bilirubin, while conjugated bilirubin is usually within the normal range and is less than 20% of the total. Levels of bilirubin in GS patients are reported to be from 20 μM to 90 μM (1.2 to 5.3 mg/dl) compared to the normal amount of < 20 μM. GS patients have a ratio of unconjugated/conjugated (indirect/direct) bilirubin commensurately higher than those without GS.

The level of total bilirubin is often further increased if the blood sample is taken after fasting for two days, and a fast can, therefore, be useful diagnostically. A further conceptual step that is rarely necessary or appropriate is to give a low dose of phenobarbital: the bilirubin will decrease substantially.

Tests can also detect DNA mutations of UGT1A1 by polymerase chain reaction or DNA fragment sequencing.

Differential diagnosis

While Gilbert's syndrome is considered harmless, it is clinically important because it may give rise to a concern about a blood or liver condition, which could be more dangerous. However, these conditions have additional indicators:

• Hemolysis can be excluded by a full blood count, haptoglobin, lactate dehydrogenase levels, and the absence of reticulocytosis (elevated reticulocytes in the blood would usually be observed in haemolytic anaemia).
• Viral hepatitis can be excluded by negative blood samples for antigens specific to the different hepatitis viruses.
• Cholestasis can be excluded by normal levels of bile acids in plasma, the absence of lactate dehydrogenase, low levels of conjugated bilirubin, and ultrasound scan of the bile ducts.
• More severe types of glucuronyl transferase disorders such as Crigler–Najjar syndrome (types I and II) are much more severe, with 0–10% UGT1A1 activity, with sufferers at risk of brain damage in infancy (type I) and teenage years (type II).
• Dubin–Johnson syndrome and Rotor syndrome are rarer autosomal recessive disorders characterized by an increase of conjugated bilirubin.
• In GS, unless another disease of the liver is also present, the liver enzymes ALT/SGPT and AST/SGOT, as well as albumin, are within normal ranges.

Treatment

Typically no treatment is needed. If jaundice is significant phenobarbital may be used.

History

Gilbert's syndrome was first described by French gastroenterologist Augustin Nicolas Gilbert and co-workers in 1901. In German literature, it is commonly associated with Jens Einar Meulengracht.

Alternative, less common names for this disorder include:

• Familial benign unconjugated hyperbilirubinaemia
• Constitutional liver dysfunction
• Familial non-hemolytic non-obstructive jaundice
• Icterus intermittens juvenilis
• Low-grade chronic hyperbilirubinemia
• Unconjugated benign bilirubinemia

Notable cases

• Napoleon I of France
• Arthur Kornberg, Nobel laureate in Physiology or Medicine, 1959
• Nicky Wire, Manic Street Preachers bassist
• Alexandr Dolgopolov (tennis player)
• Jonas Folger, MotoGP rider

References

1. ^ "Gilbert syndrome". GARD. 2016. Archived from the original on 4 August 2017. Retrieved 2 July 2017. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
2. ^ "Gilbert Syndrome". NORD (National Organization for Rare Disorders). 2015. Archived from the original on 20 February 2017. Retrieved 2 July 2017. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
3. ^ "Gilbert syndrome". Genetics Home Reference. 27 June 2017. Archived from the original on 27 June 2017. Retrieved 2 July 2017. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
4. ^ "Whonamedit - dictionary of medical eponyms". www.whonamedit.com. Archived from the original on 18 September 2016. Retrieved 2 July 2017. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
5. Kasper et al., Harrison's Principles of Internal Medicine, 16th edition, McGraw-Hill 2005
6. Boon et al., Davidson's Principles & Practice of Medicine, 20th edition, Churchill Livingstone 2006
7. Bancroft JD, Kreamer B, Gourley GR (1998). "Gilbert syndrome accelerates development of neonatal jaundice". Journal of Pediatrics. 132 (4): 656–60. doi:10.1016/S0022-3476(98)70356-7. PMID 9580766.
8. Cappellini MD, Di Montemuros FM, Sampietro M, Tavazzi D, Fiorelli G (1999). "The interaction between Gilbert's syndrome and G6PD deficiency influences bilirubin levels". British Journal of Haematology. 104 (4): 928–9. doi:10.1111/j.1365-2141.1999.1331a.x. PMID 10192462.
9. Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M (2004). "UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer". Br J Cancer. 91 (4): 678–82. doi:10.1038/sj.bjc.6602042. PMC 2364770. PMID 15280927.
10. Rauchschwalbe S, Zuhlsdorf M, Wensing G, Kuhlmann J (2004). "Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype". Int J Clin Pharmacol Ther. 42 (2): 73–7. doi:10.5414/cpp42073. PMID 15180166.
11. Kohle C, Mohrle B, Munzel PA, Schwab M, Wernet D, Badary OA, Bock KW (2003). "Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians". Biochem Pharmacol. 65 (9): 1521–7. doi:10.1016/S0006-2952(03)00074-1. PMID 12732365.
12. ^ Esteban A, Pérez-Mateo M (1999). "Heterogeneity of paracetamol metabolism in Gilbert's syndrome". European journal of drug metabolism and pharmacokinetics. 24 (1): 9–13. doi:10.1007/BF03190005. PMID 10412886.
13. ^ Gilbert Syndrome at eMedicine
14. ^ Ladislav Novotnýc; Libor Vítek (2003). "Inverse Relationship Between Serum Bilirubin and Atherosclerosis in Men: A Meta-Analysis of Published Studies". Experimental Biology and Medicine. 228 (5): 568–571. doi:10.1177/15353702-0322805-29. PMID 12709588.
15. Schwertner Harvey A; Vítek Libor (2008). "Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin". Atherosclerosis. 198 (1): 1–11. doi:10.1016/j.atherosclerosis.2008.01.001. PMID 18343383.
16. ^ Vítek L; Jirsa M; Brodanová M (2002). "Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels". Atherosclerosis. 160 (2): 449–56. doi:10.1016/S0021-9150(01)00601-3. PMID 11849670. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
17. Lin JP; O’Donnell CJ; Schwaiger JP (2006). "Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study". Circulation. 114 (14): 1476–81. doi:10.1161/CIRCULATIONAHA.106.633206. PMID 17000907. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
18. Blood Coagul Fibrinolysis. 2013 Jul;24(5):484-8. doi: 10.1097/MBC.0b013e32835e4230. The effects of Gilbert's syndrome on the mean platelet volume and other hematological parameters. Cure MC1, Cure E, Kirbas A, Cicek AC, Yuce S.
19. ^ GilbertsSyndrome.com Archived 2006-08-10 at the Wayback Machine
20. ^ Olsson R, Bliding A, Jagenburg R, Lapidus L, Larsson B, Svärdsudd K, Wittboldt S (1988). "Gilbert's syndrome—does it exist? A study of the prevalence of symptoms in Gilbert's syndrome". Acta Med Scandinavia. 224 (5): 485–490. doi:10.1111/j.0954-6820.1988.tb19615.x. PMID 3264448.
21. Bailey A, Robinson D, Dawson AM (1977). "Does Gilbert's disease exist?". Lancet. 1 (8018): 931–3. doi:10.1016/S0140-6736(77)92226-7. PMID 67389.
22. Larissa K. F. Temple; Robin S. McLeod; Steven Gallinger; James G. Wright (2001). "Defining Disease in the Genomics Era". Science Magazine. 293 (5531): 807–808. doi:10.1126/science.1062938. PMID 11486074.
23. del Giudice EM, Perrotta S, Nobili B, Specchia C, d'Urzo G, Iolascon A (October 1999). "Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis". Blood. 94 (7): 2259–62. PMID 10498597.
24. Singer, Sigal; Pilpel, Nurit; Pinhas-Hamiel, Orit (2017-01-17). "Gilbert syndrome in patients with type 1 diabetes-Prevalence, glycemic control, and microalbuminuria". Pediatric Diabetes. 18 (8): 803–807. doi:10.1111/pedi.12488. ISSN 1399-543X.
25. Videla, Luis A.; Rodrigo, Ramón; Araya, Julia; Poniachik, Jaime (2006-12). "Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease". Trends in Molecular Medicine. 12 (12): 555–558. doi:10.1016/j.molmed.2006.10.001. ISSN 1471-4914. {{cite journal}}: Check date values in: |date= (help)
26. Chang, Yoosoo; Ryu, Seungho; Zhang, Yiyi; Son, Hee Jung; Kim, Jang-Young; Cho, Juhee; Guallar, Eliseo (2012-05-15). "A Cohort Study of Serum Bilirubin Levels and Incident Non-Alcoholic Fatty Liver Disease in Middle Aged Korean Workers". PLoS ONE. 7 (5): e37241. doi:10.1371/journal.pone.0037241. ISSN 1932-6203. PMC 3352875. PMID 22615952.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
27. "Entrez Gene: UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1". Archived from the original on 2010-12-05. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
28. Raijmakers MT, Jansen PL, Steegers EA, Peters WH (2000). "Association of human liver bilirubin UDP-glucuronyltransferase activity, most commonly due to a polymorphism in the promoter region of the UGT1A1 gene". Journal of Hepatology. 33 (3): 348–351. doi:10.1016/S0168-8278(00)80268-8. PMID 11019988.
29. ^ Bosma PJ; Chowdhury JR; Bakker C; Gantla S; de Boer A; Oostra BA; Lindhout D; Tytgat GN; Jansen PL; Oude Elferink RP (1995). "The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome". New England Journal of Medicine. 333 (18): 1171–5. doi:10.1056/NEJM199511023331802. PMID 7565971. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
30. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B (1996). "Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome". Lancet. 347 (9001): 578–81. doi:10.1016/S0140-6736(96)91273-8. PMID 8596320.
31. J L Gollan; C Bateman; B H Billing (1976). "Effect of dietary composition on the unconjugated hyperbilirubinaemia of Gilbert's syndrome". Gut. 17 (5): 335–340. doi:10.1136/gut.17.5.335. PMC 1411132. PMID 1278716.
32. N Carulli; M Ponz de Leon; E Mauro; F Manenti; A Ferrari (1976). "Alteration of drug metabolism in Gilbert's syndrome". Gut. 17 (8): 581–587. doi:10.1136/gut.17.8.581. PMC 1411334. PMID 976795.
33. Gilbert A, Lereboullet P (1901). "La cholemie simple familiale". Sem Med. 21: 241–3.
34. Jens Einar Meulengracht at Who Named It?
35. Foulk, WT; Butt, HR; Owen, CA Jr; Whitcomb, FF Jr; Mason, HL (1959). "Constitutional hepatic dysfunction (Gilbert's disease): its natural history and related syndromes". Medicine (Baltimore). 38 (1): 25–46. PMID 13632313.
36. Shmaefsky, Brian (2006). "5". Biotechnology 101. Greenwood Publishing Group. p. 175. ISBN 978-0-313-33528-0. Archived from the original on 2017-11-05. {{cite book}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
37. "Wire preaches delights of three cliffs". South Wales Evening Post. 2007-04-27. p. 3.
38. David Cox. (19 April 2014). "A Tennis Player Learns to Be Aggressive for Health's Sake". New York Times. Monte Carlo. Archived from the original on 14 October 2016. {{cite news}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
39. Khorounzhiy, Valentin (2017-11-09). "Illness that 'shut down' Tech3 MotoGP rookie Jonas Folger diagnosed". Autosport.com. Motorsport Network. Retrieved 2017-11-09. After visiting specialists in his native Germany, Folger has been diagnosed with Gilbert's syndrome - a genetic ailment that precludes the liver from correctly processing bilirubin.

External links

• Gilbert's syndrome at NIH's Office of Rare Diseases
• Gilbert's Syndrome BMJ Best Practices monograph

• Accessory digestive gland disorders
• Hepatology
• Heme metabolism disorders
• Genetic syndromes
• Pediatrics
• RTT